Healthcare DIVE January 31, 2018
David Lim

More than a year after the landmark 21st Century Cures Act was signed prodding the government to evaluate use of real-world evidence, payers are weighing the role it can play to tamp down on high-cost treatments.

The bipartisan law mandated the Department of Health and Human Services create a program to evaluate the use of evidence gleaned outside randomized controlled clinical trials. The movement toward value-based care is spurring more life science companies to invest in the evidence.

Payers see their own opportunity, but some are still wary.

“When it comes to real-world evidence, especially for drug approval, there is a lot of skepticism about using less than the most rigorous randomized controlled trials,” Steve Miller, Express Scripts’ chief medical...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Cures Act, FDA, Payer, Pharma, Value Based
What Washington wants in Cures 2.0
How ONC Can Strengthen Its HTI-1 Rule To Ensure Transparency, Fairness, And Equity In AI
Providers Take Note: The Common Agreement Version 2.0 Released
Advancing Nationwide, Trusted Health Information Networks
Cures Act tied to quicker release, access of imaging reports

Share This Article